Search
Selected Filters
Filter Results
Displaying 101–110 of 117 news results
-
Jul 11, 2019
Sustained Suppression of VEGF: Looking Forward and Looking Back
The results of the LADDER trial demonstrate a major step forward but introduce many questions.
-
Jul 11, 2019
Gene Therapy Trials for Wet Age-Related Macular Degeneration
After a series of failed trials, current research suggests that the next generation of gene therapies for wet age-related macular degeneration holds promise. Learn how investigators are inducing the body’s cells to administer their own therapeutic response to disease activity.
-
May 9, 2019
Foundation Fighting Blindness Endorses 'Eye Bonds' Legislation
Bipartisan Bill Will Stimulate Up to $1 Billion in New Funding for Blindness Research
-
Mar 28, 2019
Foundation Fighting Blindness Announces Staffing Changes to Enhance Strategic Direction
The Foundation announces several staffing changes with a focus on new strategies to increase awareness and engagement with the community.
-
Aug 28, 2018
The Foundation Fighting Blindness (FFB), the world’s leading private funding source for inherited retinal disease research, announced major awards in two areas: promising research projects in retinal diseases and career development for clinical researchers.
-
Jul 19, 2018
Foundation Fighting Blindness Urges Congress to Pass ‘Eye-Bonds’ Legislation
Bill Introduced in U.S. House Would Speed Up Cures for Blindness
-
Jul 17, 2018
The Foundation Fighting Blindness Presents the Emerging Science Showcase at OIS Retina 2018
Four research and development leaders share the latest details of their groundbreaking work in therapies for retinal degenerative diseases.
-
Jul 16, 2018
Dr. Kelley brings more than 25 years of experience in developing, identifying, and advancing life science technologies to this leadership role at FFB
-
Jun 18, 2018
Three-day conference in San Diego will feature retinal science’s leading researchers and clinicians, and focus on the year’s top science and emerging treatments
-
Jun 15, 2018
The primary goal of the landmark study, funded by the Foundation, is to provide companies and researchers with disease-progression data and potential clinical trial endpoints to drive therapy development